# Monocyte‐to‐Albumin Ratio Predicts the Functional Outcome of Adults With Status Epilepticus: An Observational Study

## TL;DR

This study shows that a blood-based inflammation marker, the monocyte-to-albumin ratio, can predict poor outcomes in adults with status epilepticus.

## Contribution

The study introduces MAR as a novel, easily measurable predictor of functional outcomes in status epilepticus patients.

## Key findings

- Higher MAR at admission is independently associated with poor functional outcomes in SE patients.
- The optimal MAR cutoff for predicting poor outcomes is 13.78 with 59.38% sensitivity and 73.74% specificity.
- MAR demonstrated a moderate predictive ability with an area under the ROC curve of 0.717.

## Abstract

Status epilepticus (SE) is a serious neuro‐emergency that is often associated with unfavorable outcomes. It is known that inflammation is involved in the pathogenesis of SE, and various inflammatory markers have been suggested to be related to SE prognosis. Monocyte‐to‐albumin ratio (MAR), a novel biomarker of systemic inflammation, is derived from monocyte count and albumin levels. In this study, we sought to explore whether MAR could serve as a predictor of functional outcomes in SE.

This retrospective study collected the data of adult patients with SE. Functional outcomes of SE patients were evaluated by using the Modified Rankin Scale (mRS). Multivariable logistic regression analysis was performed to investigate the association of MAR with SE outcomes. Moreover, receiver operating characteristic (ROC) curve analysis was carried out to determine the optimal MAR threshold for predicting poor SE outcomes.

This study included 163 SE patients. Poor outcome at discharge was observed in 39.3% (64/163). Multivariate analysis showed that higher MAR at admission was independently related to unfavorable outcomes of SE patients (odds ratio: 1.092; 95% confidence interval, 1.023–1.166; p = 0.008). ROC curve analysis demonstrated that MAR could predict poor SE outcomes, with an area under the curve of 0.717 (95% CI: 0.638–0.795, p < 0.001). The optimal predictive cutoff point of MAR for poor SE outcomes was 13.78 (sensitivity 59.38%, specificity 73.74%).

Higher MAR at admission is closely correlated with an elevated risk of poor functional outcomes at discharge of SE patients. Our data suggest that MAR may be a promising and easily measurable marker for predicting short‐term SE outcomes.

Our study aimed to investigate whether the monocyte‐to‐albumin ratio (MAR), a novel marker of systemic inflammation, could serve as a predictor of functional outcomes in status epilepticus (SE).